Skip to content
Company Analysis

Biomerica, Inc. BMRA

A comprehensive view of key metrics, scores, and financial health for Biomerica, Inc.

Overview of Biomerica, Inc.

BMRA NCM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
Biomerica, Inc. (BMRA), is a Micro Cap company, in the Medical Devices industry, last closed at $1.73, about 0.0% overvalued vs fair value, -32.2% 1Y return, ranked 1068/1145 in sector.
Metrics Rev Growth -16.2% ROE -112.1% Gross Margin 8.1%
USD 1.73
0.58%
(Delayed)
• Vol 90d: 63.4%
52-Week Range
Market Cap
$7.96M
Enterprise Value
$5.72M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 89%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.biomerica.com
HQ Irvine, CA
Employees 53
Fiscal year May 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-1
$0
$0
Current: $1.73

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$4.5M
-16.2%%
Gross Profit
$362.0K
-27.3%%
Operating Income (GAAP)
-$5.3M
-3.6%%
EBITDA
-$4.9M
-3.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
8.1%
Poor

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Biomerica, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
33
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.67). Improving FCF margin signals compounding operational leverage.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.10). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.23). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
29
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 75% Coverage
Trade-Off Triangle Visualization A ternary plot showing BMRA's balance between Growth (41.9%), Profitability (26.8%), and Safety (31.3%). Growth 42% Safety 31% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

32th percentile vs peers
32
Key Signals
EPS Growth YoY 40.2% 59p Rev Growth YoY -16.2% 16p Asset Growth YoY 13.7% 77p Revenue CAGR 3Y -5.9% 17p
Strengths

No notable strengths identified for this axis.

Risks
  • Rev Growth YoY in bottom 20% of peers (-16.2%)

Profitability

20th percentile vs peers
21
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

24th percentile vs peers
24
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Biomerica, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.35
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000